HB-0017 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase I drugs for Plaque Psoriasis (Psoriasis Vulgaris) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HB-0017’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HB-0017 is under development for the treatment of moderate-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. It is administered through subcutaneous route. The drug candidate is recombinant humanized IgG1 monoclonal antibody and acts by targeting interleukin-17 A (IL-17RA) receptor.
Huabo Biopharm (Shanghai) overview
Huabo Biopharm Co Ltd (Huabobio), a subsidiary of Zhejiang Huahai Pharmaceutical Co Ltd is a developer and marketer of therapies for the treatment of patients with tumors. The company develops drugs by using bi-functional protein technology platform, domain protein technology and antibody engineering technology. Its pipeline products include HB-001, HB-002T, HB-005, HB-008, HB-016, HB-017, HB-018, HOT-1020, and HOT-3020, among others. Huabobio’s antibody engineering technology and bi-functional protein technology platform supports in developing protein and antibody drugs with improved therapeutic efficacy. The company promotes tumor metastasis at late stage of tumor progression through inducing epithelial mesenchymal transition, inhibiting tumor immunity; and tumor angiogenesis through induction of angiogenic mediators such as vascular endothelial growth factor. Huabobio is headquartered in Shanghai, China.
For a complete picture of HB-0017’s drug-specific PTSR and LoA scores, buy the report here.